• linkedin
  • Increase Font
  • Sharebar

    Biologic use beyond psoriasis



    1.     Daniel BS, Murrell DF, Joly P. Rituximab and its use in autoimmune bullous disorders. Dermatol Clin. 2011 Oct;29(4):571-5. http://www.ncbi.nlm.nih.gov/pubmed/21925000

    2.     Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update.Drugs. 2015 Feb;75(3):271-84. doi: 10.1007/s40265-015-0353-6. http://www.ncbi.nlm.nih.gov/pubmed/25655250

    3.     Wang HH, Liu CW, Li YC, Huang YC. Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens. Acta Derm Venereol.2015 Apr 17. http://www.ncbi.nlm.nih.gov/pubmed/25881672

    4.     Di Stefani A, Galluzzo M, Talamonti M, Chiricozzi A, Costanzo A, Chimenti S.Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. J  Dermatol Case Rep. 2013 Mar 30;7(1):5-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=Di+Stefani+A%2C+Galluzzo+M%2C+Talamonti+M%2C+Chiricozzi+A%2C+Costanzo+A%2C+Chimenti+S.

    Disclosure: None (Note: Dr. Heffernan had ties to most of the companies making biologics but hasn’t for two to three years. Today, he is senior medical director for Eli Lilly and Company, but didn’t talk about Eli Lilly medications in this story.) 

    Lisette Hilton
    Lisette Hilton is president of Words Come Alive, based in Boca Raton, Florida.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow